The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson's disease: A multicenter, double-blind, randomized, placebo-controlled study

Parkinsonism and Related Disorders

Volumn 19, Issue 11, 2013, Pages 1022-1026

  Zhang, Zhenxin ^a   Wang, Jian ^b   Zhang, Xiaoying ^c   Chen, Shengdi ^d   Wang, Zhenfu ^e   Zhang, Baorong ^f   Liu, Chunfeng ^g   Qu, Qiumin ^h   Cheng, Yan ⁱ   Li, Jie ^j   Cao, Haijun ^j   Cai, Meng ^j   Zhu, Rongxuan ^j  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b FUDAN UNIVERSITY   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^e CHINESE PLA GENERAL HOSPITAL   (China)

^f THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^g THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^h THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

ⁱ TIANJIN MEDICAL UNIVERSITY   (China)

^j GLAXOSMITHKLINE   (China)

more..

Author keywords

Chinese subjects; Parkinson's disease; Ropinirole PR

Indexed keywords

LEVODOPA; PLACEBO; ROPINIROLE;

ABDOMINAL DISCOMFORT; ADD ON THERAPY; ADULT; ARTICLE; ASTHENIA; BLURRED VISION; CHINESE; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; DYSKINESIA; ELEVATED BLOOD PRESSURE; FALLING; FATIGUE; FEMALE; HALLUCINATION; HEART ARRHYTHMIA; HEART PALPITATION; HUMAN; HYPERTENSION; INSOMNIA; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MOBILIZATION; MULTICENTER STUDY; NAUSEA; ORTHOSTATIC HYPOTENSION; PARALLEL DESIGN; PARKINSON DISEASE; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RECOMMENDED DRUG DOSE; RHINOPHARYNGITIS; SIDE EFFECT; SOMNOLENCE; TOOTH PAIN; TREATMENT DURATION; UNIFIED PARKINSON DISEASE RATING SCALE; UPPER RESPIRATORY TRACT INFECTION; VERTIGO; WEIGHT REDUCTION;

CHINESE SUBJECTS; PARKINSON'S DISEASE; ROPINIROLE PR;

AGED; ANTIPARKINSON AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INDOLES; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; TABLETS, ENTERIC-COATED; TREATMENT OUTCOME;

EID: 84886599290     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2013.07.009     Document Type: Article

References (22)

1. Adler C.H., Sethi K.D., Hauser R.A., Davis T.L., Hammerstad J.P., Beroni J., et al. Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group. Neurology 1997, 49:393-399.
2. Brooks D.J., Abbott R.J., Lees A.J., Martigononi E., Philcox D.V., Rascol O., et al. Aplacebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease. Clin Neuropharmacol 1998, 21:101-107.
3. Lieberman A., Olanow C.W., Sethi K., Swanson P., Waters C.H., Fahn S., et al. Amulticenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group. Neurology 1998, 51:1057-1062.
4. Korczyn A.D., Brunt E.R., Larsen J.P., Nagy Z., Poewe W.H., Ruggieri S. A3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 Study Group. Neurology 1999, 53:364-370.
5. Brunt E.R., Brooks D.J., Korczyn A.D., Montatruc J.L., Stocchi F. Asix-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa. JNeural Transm 2002, 109:489-502. 043 Study Group.
6. Lieberman A.N., Neophytides A., Leibowitz M., Gopinathan G., Pact V., Walker R., et al. Comparative efficacy of pergolide and bromocriptine in patients with advanced Parkinson's disease. Adv Neurol 1983, 37:95-108.
7. Weil C. The safety of bromocriptine in long-term use: a review of the literature. Curr Med Res Opin 1986, 10:25-51.
8. Langtry H.D., Clissold S.P. Pergolide: a review of its pharmacological properties and therapeutic potential in Parkinson's disease. Drugs 1990, 39:491-506.
9. Goetz C.G., Tanner C.M., Glantz R.H., Klawans H.L. Chronic agonist therapy for Parkinson's disease: a 5-year study of bromocriptine and pergolide. Neurology 1985, 35:749-751.
10. Pahwa R., Stacy M.A., Factor S.A., Lyons K.E., Stocchi F., Hersh B.P., et al. Ropinirole 24-hour prolonged release: randomized, controlled study in Parkinson disease. Neurology 2007, 68:1108-1115. EASE-PD Adjunct Study Investigators.
11. Yasuda S.U., Zhang L., Huang S.-M. The role of ethnicity in variability in response to drugs; focus on clinical pharmacology studies. Clin Pharmacol Ther 2008, 84:417-423.
12. Liu H, Jian J, Want H, Chen X, Liu T, Cao H, etal. A single and multiple dose study to investigate the pharmacokinetics of a prolonged release formulation of ropinirole in healthy Chinese subjects. Clin Pharmacol Drug Dev, in press.
13. Hauser R.A., Friedlander J., Zesiewicz T.A., Adler C.H., Seeberger L.C., O'Briend C.F., et al. Ahome diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. Clin Neuropharmacol 2000, 23:75-81.
14. Recent developments in Parkinson's disease 1987, vol. 2:153-163. Macmillan Health Care Information, Florham Park, NJ.
15. Hamilton M. Arating scale for depression. JNeurol Neurosurg Psychiatry 1960, 23:56-62.
16. Chaudhuri K.R., Pal S., DiMarco A., Whately-Smith C., Bridgman K., Mathew R., et al. The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease. JNeurol Neurosurg Psychiatry 2002, 73:629-635.
17. Peto V., Jenkinson C., Fitzpatrick R. PDDQ-39: a review of the development, validation and application of a PD quality of life questionnaire and its associated measures. JNeurol 1998, 245(Suppl.1):S10-S14.
18. Guy W. Clinical global impression. ECDEU assessment manual for psychopharmacology, revised 1976, 217-222. US Department of Health Education and Welfare, Rockville, MD.
19. Kim S.W., Grant J.E., Adson D.E., Shin Y.C. Double blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry 2001, 49:914-921.
20. Kieburtz K., Hubble J. Benefits of COMT inhibitors in levodopa-treated parkinsonian patients results of clinical trials. Neurology 2000, 55(11 Suppl.4):S42-S45. discussion S46-50.
21. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 1997, 42:747-755. Parkinson Study Group.
22. Rinne U.K., Larsen J.P., Siden A., Worm-Petersen J. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 1998, 51:1309-1314.